Gómez Campderá F J, López Gómez J M, Cervera A, Gómez Campderá J, Canals M J, Morales J L, Luque A
An Esp Pediatr. 1984 May;20(8):771-6.
Mechlorethamine has been assessed in 28 patients with idiopathic nephrotic syndrome previously treated with prednisone only. One patient was cortico-resistant (CR), 22 cortico-dependent (CD) and 5 patients had frequent relapses (FR). FR patients had not histological examination and CR patient had a global focal sclerosis (GFS). Among CD patients, 12 had minimal change nephropathy (MCN) and 10 had a diffuse mesangial proliferation (DMP). After prednisone treatment was started, 0.1 mg/kg/d of mechlorethamine for four days was administered iv, in hospital and repeated one month later. After mechlorethamine treatment, GFS evolution was unchanged. Among FR, all the patients improved, 3 with complete remission and 2 with infrequent relapses. MNC improved in 66.6% and DMP in 40%, with the best evolution in immunofluorescence negative patients. Among early side effects, we found gastrointestinal disorders in 11 cases (39.2%) and leukopenia in 8 (28.2%), that required discontinuation of treatment in only 2 cases. We have not assessed gonadal toxicity. We comment the evolution after treatment of the different histological patterns, comparing with other nitrogen mustards and we conclude that mechlorethamine is useful in FR and CD idiopathic nephrotic syndrome corresponding to MCN or DMP with negative inmunofluorescence. Results with other nitrogen mustards, especially chlorambucil, are better.
对28例此前仅接受过泼尼松治疗的特发性肾病综合征患者使用了氮芥进行评估。1例患者为皮质激素抵抗(CR),22例为皮质激素依赖(CD),5例患者频繁复发(FR)。FR患者未进行组织学检查,CR患者有全球局灶性硬化(GFS)。在CD患者中,12例为微小病变性肾病(MCN),10例为弥漫性系膜增生(DMP)。开始泼尼松治疗后,静脉注射0.1mg/kg/d的氮芥,持续4天,在医院进行,1个月后重复。氮芥治疗后,GFS进展未改变。在FR患者中,所有患者均有改善,3例完全缓解,2例复发不频繁。MCN患者中66.6%改善,DMP患者中40%改善,免疫荧光阴性患者的病情进展最佳。在早期副作用方面,我们发现11例(39.2%)有胃肠道疾病,8例(28.2%)有白细胞减少,仅2例需要停药。我们未评估性腺毒性。我们比较了不同组织学类型治疗后的病情进展,并与其他氮芥类药物进行了比较,得出结论:氮芥对FR和CD型特发性肾病综合征(对应MCN或DMP且免疫荧光阴性)有用。其他氮芥类药物,尤其是苯丁酸氮芥,效果更好。